Antoni Ribas, MD, PhD | Authors

ASCO: Impact of 2 New Drugs for the Treatment of Metastatic Melanoma

August 19, 2011

Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.